超越实验室:对他类药物的临床影响
Julian P J Halcox1, John E Deanfield
1Vascular Physiology Unit, Department of Cardiology, Institute of Child Health, University College London, London, England.
Circulation
|June 3, 2004
概括
类他类药物,或3 - 基-3 - 甲基氨酸-辅酶A减少酶抑制剂,提供超出降脂的好处. 目前的证据表明,降低胆固醇仍然是它们临床有效性的主要驱动因素.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 3-基-3-甲基氨基-协酶A (HMG-CoA) 减少酶抑制剂 (他类药物) 已经彻底改变了动脉样硬化管理.
- 类药物会影响脂质水平,并影响炎症,氧化和血栓性通路.
- 这些类效应可能有助于观察到超出脂质修饰的临床益处.
研究的目的:
- 审查关于他类药物的临床证据,这些证据独立于降脂效应.
- 为了探索在通常与高胆固醇无关的条件下,他的实用性.
- 评估好处是否先于脂质水平变化,以及大小是否与胆固醇无关.
主要方法:
- 审查临床试验数据和科学文献.
- 对检查他类药物的类效应的证据分析.
- 评估临床结果与脂质减少之间的关系.
主要成果:
- 虽然他类药物具有性作用,但降低低密度脂蛋白 (LDL) 目前被认为是临床益处的主要机制.
- 独立于降低LDL的显著临床益处的证据有限.
- 临床益处的大小通常与LDL胆固醇降低的程度相关.
结论:
- 降低低密度脂蛋白仍然是驱动他类药物治疗临床益处的主要机制.
- 类固醇药物治疗应继续专注于降低脂质以减轻心血管风险.
- 进一步的研究可能会阐明在特定背景下类效应的作用和程度.
相关概念视频
Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


